The Future of Care—In the Community
Under the leadership of Dr. Judith Rose, the research team participates in clinical research trials that capitalize on our PET/CT, and Nuclear Medicine expertise. Our experience in these advanced modalities—combined with our rigorous methodology and our relationship to the communities we serve—makes us a sought-after partner for drug and device manufacturers as well as for contract research organizations (CROs). In collaboration with RadNet, an outpatient imaging provider with a national profile, we are able to conduct research consistently across a broad patient population, while controlling quality and efficiency.
As sophisticated radiopharmaceuticals are developed to identify disease markers (such as beta-amyloid, a biological marker of Alzheimer’s Disease), testing depends on imaging to track metabolic activity in the areas targeted by those drugs. A natural follow-on is the development of drugs that can treat pathology in those same areas, once it’s discovered, and advanced imaging techniques are again required. They enable researchers to evaluate how or if the new drugs are working. We are making important contributions in that field across RadNet’s large network.
Quality & Experience
The research team has participated in multiple clinical trials that use advanced imaging, from molecular diagnostics to dosimetry, and with partners like GE, Eli Lilly, Eisai, Merck, and many others. Our protocol includes standardization across multiple states, and reading workflows that ensure quality and continuous education. In one study, for example, more than a dozen RadNet radiologists went through special training for reading exams that made use of a new tracer—training recommended by the drug manufacturer. Dr. Rose instituted a double-read protocol, and all certified radiologists could view the exams on a special centralized server. Quality measures are built in to all our research activities.
Partnering with Community Physicians
We team with physicians in the community to provide quality imaging for their clinical trials. We have experience in following protocols, contributing data, understanding research budgets, and performing high quality reads in advanced modalities. Physicians know that they are teaming with a well-developed research group that can play a valuable role in the imaging component of their clinical trials, and that we offer a familiar and comfortable local setting for their patients.
Society for Nuclear Medicine Clinical Trials Network
Standardization in molecular imaging is critical for a clinical trial to be successful. To achieve CTN validation, a site must demonstrate that it complies with common quality control metrics and that it is able to acquire high-quality PET images and interpret them correctly. RadNet has achieved SNM validation at nine of our imaging centers across the U.S.